Race and the linkage between serum prostate-specific antigen and prostate cancer: A study of American veterans

American Journal of Clinical Pathology

Volumn 122, Issue 3, 2004, Pages 338-344

  Vollmer, Robin T ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Nomograms; Prostate cancer; Prostate specific antigen; Race; Risk factors; Serum PSA; Tumor mass

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER GRADING; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CAUCASIAN; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; RACE; RACE DIFFERENCE; REGRESSION ANALYSIS; TUMOR VOLUME;

EID: 4344647928     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/QVA7YRHKF8VUCNRV     Document Type: Article

References (45)

1. Brawley OW, Knopf K, Merrill R. The epidemiology of prostate cancer, part I: descriptive epidemiology. Semin Urol Oncol. 1998;16:187-192.
2. Centers for Disease Control and Prevention. Recent trends in mortality rates for four major cancers by sex and race/ethnicity, United States, 1990-1998. MMWR Morb Mortal Wkly Rep. 2002;51:49-53.
3. Polednak AP, Flanner JT. Black versus white racial differences in clinical stage at diagnosis and treatment of prostatic cancer in Connecticut. Cancer. 1992;70:2152-2158.
4. Tarman GJ, Kane CJ, Moul JW, et al. Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care system. Urology. 2000;56:1016-1020.
5. Powell IJ, Dey J, Dudley A, et al. Disease-free survival difference between African Americans and whites after radical prostatectomy for local prostate cancer: a multivariable analysis. Urology. 2002;59:907-912.
6. Paquette EL, Connelly RR, Sesterhenn IA, et al. Improvements in pathologic staging for African-American men undergoing radical retropubic prostatectomy during the prostate specific antigen era. Cancer. 2001;92:2673-2679.
7. Cross CK, Shultz D, Malkowicz SB, et al. Impact of race on prostate-specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate. J Clin Oncol. 2002;20:2863-2868.
8. Freedland SJ, Amling CL, Dorey F, et al. Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology. 2002;60:670-674.
9. Blanco FJ, Wood DP Jr, Grignon DJ, et al. Prostate cancer stage shift has eliminated the gap in disease-free survival in black and white American men after radical prostatectomy. J Urol. 2002;168:479-482.
10. Powell IJ, Banerjee M, Sakr W, et al. Should African-American men be tested for prostate carcinoma at an earlier age than white men? Cancer. 1999;85:472-477.
11. Badalament RA, O'Toole RV, Young DC, et al. DNA ploidy and prostate-specific antigen as prognostic factors in clinically resectable prostate cancer. Cancer. 1991;67:3014-3023.
12. Vijayakumar S, Karrison T, Weichselbaum RR, et al. Racial differences in prostate-specific antigen levels in patients with local-regional prostate cancer. Cancer Epidemiol Biomarkers Prev. 1992;1:541-545.
13. Moul JW, Sesterhenn IA, Connelly RR, et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA. 1995;274:1277-1281.
14. Moul JW, Douglas TH, McCarthy WF, et al. Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J Urol. 1996;155:1667-1673.
15. Powell IJ, Heilbrun LK, Sakr W, et al. The predictive value of race as a clinical prognostic factor among patients with clinically localized prostate cancer: a multivariate analysis of positive surgical margins. Urology. 1997;49:726-731.
16. Vijayakumar S, Winter K, Sause W, et al. Prostate-specific antigen levels are higher in African-American than in white patients in a multicenter registration study: results of RTOG 94-12. Int J Radiat Oncol Biol Phys. 1998;40:17-25.
17. Iselin CE, Box JW, Vollmer RT, et al. Surgical control of clinically localized prostate carcinoma is equivalent in African-American and white males. Cancer. 1998;83:2352-2360.
18. Pettaway C, Troncoso P, Ramirez EI, et al. Prostate specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens. J Urol. 1998;160:437-442.
19. Moul JW, Connelly RT, Mooneyhan RM, et al. Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients. J Urol. 1999;162:394-397.
20. Fowler JE, Bigler SA. A prospective study of the serum prostate specific antigen concentrations and Gleason histologic scores of black and white men with prostate carcinoma. Cancer. 1999;86:836-841.
21. Eastham JA, Kattan MW. Disease recurrence in black and white men undergoing radical prostatectomy for clinical stage T1-T2 prostate cancer. J Urol. 2000;163:143-145.
22. Freedland SJ, Dorey F, Aronson WJ. Multivariate analysis of race and adverse pathologic findings after radical prostatectomy. Urology. 2000;56:807-811.
23. Zhang W, Sesterhenn IA, Connelly RR, et al. Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference in prostate specific antigen. J Urol. 2000;163:131-136.
24. Fowler JE, Bigler SA, Farabaugh PB. Prospective study of cancer detection in black and white men with normal digital rectal examination but prostate specific antigen equal or greater than 4.0 ng/mL. Cancer. 2002;94:1661-1667.
25. Gaston KE, Kim D, Singh S, et al. Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J Urol. 2003;170:990-993.
26. Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909-916.
27. Palken M, Cobb OE, Warren BH, et al. Prostate cancer: correlation of digital rectal examination, transrectal ultrasound and prostate specific antigen levels with tumor volumes in radical prostatectomy specimens. J Urol. 1990;143:1155-1162.
28. Partin AW, Carter HB, Chan DW, et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol. 1990;143:747-752.
29. Babaian RJ, Troncoso P, Steelhammer LC, et al. Tumor volume and prostate specific antigen: implication for early detection and defining a window of curability. J Urol. 1995;154:1808-1812.
30. Humphrey PA, Vollmer RT. Relationships between serum prostate-specific antigen and histopathologic appearances of prostate carcinoma. In Foster CS, Bostwick DG, eds. Pathology of the Prostate. Philadelphia, PA: Saunders; 1998:253-281.
31. Stamey TA, Johnstone IM, McNeal JE, et al. Preoperative serum prostate specific antigen levels between 2 and 22 ng/mL correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng/mL. J Urol. 2002;167:103-111.
32. Vollmer RT, Humphrey PA. Tumor volume in prostate cancer and serum prostate-specific antigen: analysis from a kinetic viewpoint. Am J Clin Pathol. 2003;119:80-89.
33. Humphrey PA, Vollmer RT. Percentage carcinoma as a measure of prostatic tumor size in radical prostatectomy tissues. Mod Pathol. 1997;10:326-333.
34. Sawyer R, Berman JJ, Borkowski A, et al. Prostate-specific antigen in black men [letter]. Lancet. 1996;347:1329.
35. Morgan TO, Jacobsen SJ, McCarthy WF, et al. Age-specific reference ranges for serum prostate-specific antigen in black men. N Engl J Med. 1996;335:304-310.
36. Henderson RJ, Eastham JA, Culkin DJ, et al. Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer. J Natl Cancer Inst. 1997;89:134-138.
37. Fowler JE Jr, Bigler SA, Kilambi NK, et al. Relationships between prostate-specific antigen and prostate volume in black and white men with benign prostate biopsies. Urology. 1999;53:1175-1178.
38. Smith DS, Carvalhal GF, Mager DE, et al. Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men. J Urol. 1998;160:1734-1738.
39. Casella G, Berger RL. Statistical Inference. 2nd ed. Pacific Grove, CA: Duxbury; 2002.
40. Partin AW, Kattan MW, Subong ENP, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer; a multi-institutional update. JAMA. 1997;277:1445-1451.
41. Kattan MW, Eastham JA, Stapleton AM, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Institute. 1998;90:766-771.
42. Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143:401-409.
43. Demark-Wahnefried W, Price DT, Polascik TJ, et al. A pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer pre-surgery: exploring effects on hormonal levels, PSA and histopathology. Urology. 2001;58:47-52.
44. Harlan L, Brawley O, Pommerenke F, et al. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol. 1995;13:93-100.
45. Mettlin CJ, Murphy GP, Cunningham MP, et al. The National Cancer Data Base report on race, age, and region variations in prostate cancer treatment. Cancer. 1997;80:1261-1266.